Cantor Fitzgerald Has Negative View of ZVRA FY2025 Earnings

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings estimate for Zevra Therapeutics from $1.58 to $0.99 per share while maintaining an "Overweight" rating with a $29.00 target price.
• Zevra Therapeutics reported a quarterly EPS of (0.06), significantly missing the consensus estimate of $1.43 by $1.49, despite revenues exceeding expectations at $25.88 million.
• Institutional investors are actively increasing their stakes in Zevra Therapeutics, with a notable 462.4% increase in holdings by Adage Capital Partners GP L.L.C. in the fourth quarter.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities researchers at Cantor Fitzgerald reduced their FY2025 EPS estimates for Zevra Therapeutics in a research report issued on Wednesday, August 13th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings of $0.99 per share for the year, down from their prior forecast of $1.58. Cantor Fitzgerald currently has a "Overweight" rating and a $29.00 price target on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. Cantor Fitzgerald also issued estimates for Zevra Therapeutics' FY2026 earnings at $0.55 EPS.

A number of other brokerages have also recently issued reports on ZVRA. JMP Securities reduced their price objective on shares of Zevra Therapeutics from $19.00 to $18.00 and set a "market outperform" rating on the stock in a research note on Wednesday, August 13th. HC Wainwright initiated coverage on Zevra Therapeutics in a research report on Wednesday, July 2nd. They set a "buy" rating and a $26.00 target price for the company. Wall Street Zen lowered Zevra Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 20th. Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, August 13th. Finally, Zacks Research lowered Zevra Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $23.71.

Zevra Therapeutics Trading Up 3.0%

ZVRA stock traded up $0.27 during midday trading on Friday, reaching $9.28. The company's stock had a trading volume of 859,544 shares, compared to its average volume of 734,119. Zevra Therapeutics has a 52 week low of $6.19 and a 52 week high of $13.16. The stock has a market cap of $520.93 million, a PE ratio of -44.19 and a beta of 1.87. The company has a quick ratio of 7.81, a current ratio of 7.85 and a debt-to-equity ratio of 0.52. The business's 50-day simple moving average is $10.55 and its 200-day simple moving average is $8.78.

Institutional Investors Weigh In On Zevra Therapeutics

Several institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC lifted its stake in Zevra Therapeutics by 617.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company's stock valued at $88,000 after acquiring an additional 8,552 shares in the last quarter. Rubric Capital Management LP lifted its stake in Zevra Therapeutics by 60.8% in the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company's stock valued at $17,253,000 after acquiring an additional 740,584 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Zevra Therapeutics by 1,240.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 42,950 shares of the company's stock valued at $378,000 after acquiring an additional 39,746 shares in the last quarter. Bank of America Corp DE lifted its stake in Zevra Therapeutics by 150.4% in the 2nd quarter. Bank of America Corp DE now owns 223,852 shares of the company's stock valued at $1,972,000 after acquiring an additional 134,437 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its stake in Zevra Therapeutics by 15.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company's stock valued at $36,720,000 after acquiring an additional 550,000 shares in the last quarter. Institutional investors own 35.03% of the company's stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.